Resources

In this week's Homerun Slides, liraglutide's effects on and action in diabetes, and therapeutic ways to treat chronic kidney disease in people with type 2.

Altered metabolites and their potential origins in type 2 diabetes and insulin resistance: In recent years, a large number of cross-sectional and prospective studies have revealed specific metabolites and pathways that are altered by, or predictive of, T2DM and insulin resistance.

In this Exclusive Interview, Dr. Osama Hamdy talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the importance of understanding and working with various cultural traditions in order to effectively manage diabetes anywhere in the world.

New study finds that adults with type 2 diabetes and atherosclerotic cardiovascular disease have increased risk of mortality with a prior nonfatal cardiovascular (CV) event.

Large cohort suggests supplement increase beneficial in women of reproductive age.

Once-weekly exenatide formulation can provide as much benefit as the traditional twice-daily dosing.

High linoleic acid level could reduce type 2 risk by 43 percent, new study found.

What do you use to diagnose prediabetes a majority of the time? 1) HbA1c 2) Fasting BG 3) IGTT 4) Other Follow the link to see how you compare to your colleagues.

A 43-year-old patient with a 2-year history of type 2 diabetes presents to your office for a follow-up visit. She is a highly motivated patient and doesn’t have any significant co-morbidities, so together, you have set a target A1C= 6.5%. Her current medications are metformin and sulfonylurea. Despite her good efforts, her current A1C is 7.3%. You would like to add a third agent to her regimen, however, she is concerned about any additional weight gain as she has gained a few pounds since starting the sulfonylurea. Which drug class would you add to minimize any additional weight gain? A. Basal insulin B. GLP-1 agonist C. Thiazolidine D. DPP-4 Inhibitor

The FDA has approved an auto-injector and new formulation of a once-weekly treatment for type 2 diabetes from AstraZeneca. Bydureon BCise offers a single-dose auto-injector for adults with type 2 diabetes. Bydureon BCise features a unique continuous-release microsphere technology delivery system that provides consistent levels of the product’s active ingredient, exenatide. The new formulation has shown the ability to reduce blood sugar levels alongside weight loss, despite not being a weight loss medication.